Gilead Expands Hep C Portfolio With LG Life Sciences Deal
This article was originally published in PharmAsia News
Executive Summary
Gilead Sciences is gaining a Phase II pan-caspase inhibitor for hepatitis C through a licensing agreement with LG Life Sciences worth up to $202 million announced Nov. 7